Skip to main content
. Author manuscript; available in PMC: 2017 Sep 8.
Published in final edited form as: Arch Pharm Res. 2016 Jun 27;39(7):897–911. doi: 10.1007/s12272-016-0784-y

Table 3.

Results of binding affinity assay of compounds 122 for human cannabinoid (subtypes CB1 and CB2) and opioid receptors (subtypes δ, κ, and μ)

Compounds CB1 % Displacement CB2 % Displacement δ % Displacement κ % Displacement μ % Displacement
1 5.3
2
3 15.9 6.9
4 36.9 69.7 11.7 9.1
5 7.7
6 2.9 22.2 3.1 16.7 23
7 1.7 14.8 12.9
8 39.1 0.4 22.8 22.1
9 9.1 7.3 7.6
10 15.8 9.2 7.5
11 11.3 62.5 7 11.5
12 11.8 5.5 36.1
13 24.9 17.5 28.1
14 44.5 13.2 16.1
15 44.4 86.6 2.7 1.9
16 22.4 17.1 16.7 5.8
17 4.7 30.9 5.2
18 3.4 10.7 7.1
19 22.8 2.6
20 7 28.5
21 3.4 26.5 8.9
22 32.2 21.2
CP-55,940 91.49 103.34
Naloxone 99.11 101.43 101.92